KRD appears more active, less safe than KCD in newly diagnosed MM



Micrograph showing MM
New research suggests one triplet regimen may be more active but also more toxic than another in patients with newly diagnosed multiple myeloma (MM). In the FORTE trial, the combination of carfilzomib, lenalidomide, and dexamethasone (KRD) produced higher response rates than carfilzomib, cyclophosphamide, and dexamethasone (KCD). However, treatment with KRD... [Read Article]

Common insurance plans exclude NCI, NCCN cancer centers



Cancer patient
receiving chemotherapy
Photo by Rhoda Baer
Narrow insurance plan coverage may prevent US cancer patients from receiving care at “high-quality” cancer centers, according to research published in the Journal of Clinical Oncology. Researchers found that “narrow network” insurance plans—lower-premium plans with reduced access to certain providers—are more likely to exclude doctors associated... [Read Article]

FDA puts pembrolizumab trials on clinical hold



Pembrolizumab (Keytruda)
Photo courtesy of Merck
The US Food and Drug Administration (FDA) has placed clinical holds on 3 trials testing combination therapy with pembrolizumab (Keytruda) in patients with multiple myeloma (MM)—KEYNOTE-183, KEYNOTE-185, and KEYNOTE-023. In 2 of these trials—KEYNOTE-183 and -185—there were more deaths among patients receiving pembrolizumab than among patients receiving... [Read Article]

FDA clears use of reagents to detect hematopoietic neoplasia



Blood samples
Photo by Graham Colm
The US Food and Drug Administration (FDA) has allowed marketing of the ClearLLab Reagent Panel, a combination of conjugated antibody cocktails designed to aid the detection of hematopoietic neoplasia. This includes chronic and acute leukemias, non-Hodgkin lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. The ClearLLab reagents are... [Read Article]

Single-dose NEPA found non-inferior to aprepitant/granisetron



Nurse hanging bags
of chemotherapy drugs
Photo by Bill Branson
In a head-to-head study comparing a single-dose oral antiemetic to a 3-day oral regimen, the single dose has shown itself to be non-inferior to the multi-day regimen in preventing chemotherapy-induced nausea and vomiting (CINV). The investigators evaluated netupitant/palonosetron (NEPA) against aprepitant/granisetron (APR/GRAN) in patients on... [Read Article]

FDA approves daratumumab-POM-Dex combo for MM



Daratumumab (Darzalex)
Photo courtesy of Janssen
The US Food and Drug Administration (FDA) has approved daratumumab (Darzalex®) in combination with pomalidomide (POM) and dexamethasone (dex) for the treatment of multiple myeloma (MM) in patients who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor (PI). The FDA previously approved daratumumab in... [Read Article]

Large MM trial finds denosumab non-inferior to ZA for SRE



Attendees at ASCO 2017
Annual Meeting
Photo © ASCO/Scott Morgan 2017
The largest international multiple myeloma (MM) trial ever conducted, according to the trial sponsor, met its primary endpoint, demonstrating that denosumab is non-inferior to zoledronic acid (ZA) in delaying the time to first on-study skeletal-related event (SRE) in patients with MM. In addition to bone-specific... [Read Article]